1201186-57-3

Basic information

• Product Name: 2-hydrazinyl-5-[(4-methylphenyl)sulfonyl]-5H-Pyrrolo[2,3-b]pyrazine
• Synonyms: 2-hydrazinyl-5-[(4-methylphenyl)sulfonyl]-5H-Pyrrolo[2,3-b]pyrazine
• CAS NO: 1201186-57-3
• Molecular Weight: 303.345
• Mol File: 1201186-57-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-hydrazinyl-5-[(4-methylphenyl)sulfonyl]-5H-Pyrrolo[2,3-b]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-hydrazinyl-5-[(4-methylphenyl)sulfonyl]-5H-Pyrrolo[2,3-b]pyrazine(1201186-57-3)
• EPA Substance Registry System: 2-hydrazinyl-5-[(4-methylphenyl)sulfonyl]-5H-Pyrrolo[2,3-b]pyrazine(1201186-57-3)

Safety Data

• Hazardous Substances Data: 1201186-57-3(Hazardous Substances Data)

Upstream product

• 1421338-19-3 C₂₃H₂₉N₅O₆S 
• 1201186-54-0 2-bromo-5-(p-toluenesulfonyl)-5H-pyrrolo[2,3-b]pyrazine 
• 875781-41-2 5-bromo-3-((trimethylsilyl)ethynyl)pyrazine-2-amine 
• 870-46-2 t-butoxycarbonylhydrazine 

Downstream Products

• 1201181-84-1 1-(tetrahydro-2H-pyran-4-yl)-6H-pyrrolo[2,3-e][1, 2, 4]triazolo[4,3-a]pyrazine 
• 1201186-94-8 tert-butyl (1S,3R)-3-(2-(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)hydrazinecarbonyl)cyclopentylcarbamate 
• 1201186-05-1 1-cyclohexyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazine 
• 1421338-20-6 C₂₀H₂₃N₅O₃S 
• 1201192-18-8 N-((1S,3R)-3-(6-tosyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-1-yl)cyclopentyl)ethanesulfonamide 
• 1201192-20-2 N-((1S,3R)-3-(6-tosyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-1-yl)cyclopentyl)propane-1-sulfonamide 

Relevant articles and documents

Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors

Previous work investigating tricyclic pyrrolopyrazines as kinase cores led to the discovery that 1-cyclohexyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazine (12) had Jak inhibitory activity. Herein we describe our initial efforts to develop orally bioavailable analogs of 12 with improved selectivity of Jak1 over Jak2.

Novel Tricyclic Compounds

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.